Literature DB >> 8528576

Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on mitochondrial respiration in ischaemic dog hearts.

K Satoh1, A Yamato, T Nakai, K Hoshi, K Ichihara.   

Abstract

1. Effects of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, pravastatin and simvastatin, on the myocardial level of coenzyme Q10, and on mitochondrial respiration were examined in dogs. 2. Either vehicle (control), pravastatin (4 mg kg-1 day-1), or simvastatin (2 mg kg-1 day-1) was administered orally for 3 weeks. First, the myocardial tissue level of coenzyme Q10 was determined in the 3 groups. Second, ischaemia was induced by ligating the left anterior descending coronary artery (LAD) in anaesthetized open chest dogs, pretreated with the inhibitors. After 30 min of ischaemia, nonischaemic and ischaemic myocardium were removed from the left circumflex and LAD regions, respectively, and immediately used for isolation of mitochondria. The mitochondrial respiration was determined by polarography, with glutamate and succinate used as substrates. 3. Simvastatin significantly decreased the myocardial level of coenzyme Q10, but pravastatin did not. 4. Ischaemia decreased the mitochondrial respiratory control index (RCI) in both groups. Significant differences in RCI between nonischaemic and ischaemic myocardium were observed in the control and simvastatin-treated groups. 5. Only in the simvastatin-treated group did ischaemia significantly decrease the ADP/O ratio, determined with succinate. 6. The present results indicate that simvastatin but not pravastatin may cause worsening of the myocardial mitochondrial respiration during ischaemia, probably because of reduction of the myocardial coenzyme Q10 level.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8528576      PMCID: PMC1909075          DOI: 10.1111/j.1476-5381.1995.tb16679.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  22 in total

1.  Techniques for the application of polarography to mitochondrial respiration.

Authors:  B HAGIHARA
Journal:  Biochim Biophys Acta       Date:  1961-01-01

2.  Respiratory enzymes in oxidative phosphorylation. III. The steady state.

Authors:  B CHANCE; G R WILLIAMS
Journal:  J Biol Chem       Date:  1955-11       Impact factor: 5.157

3.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

4.  Pravastatin, lipids, and major coronary events.

Authors:  C D Furberg; R P Byington; J R Crouse; M A Espeland
Journal:  Am J Cardiol       Date:  1994-06-01       Impact factor: 2.778

Review 5.  Regulation of HMG-CoA reductase.

Authors:  V W Rodwell; J L Nordstrom; J J Mitschelen
Journal:  Adv Lipid Res       Date:  1976

6.  Influence of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on mitochondrial respiration in rat liver during ischemia.

Authors:  K Satoh; T Nakai; K Ichihara
Journal:  Eur J Pharmacol       Date:  1994-08-03       Impact factor: 4.432

7.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

Authors: 
Journal:  Lancet       Date:  1994-11-19       Impact factor: 79.321

8.  CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal species.

Authors:  Y Tsujita; M Kuroda; Y Shimada; K Tanzawa; M Arai; I Kaneko; M Tanaka; H Masuda; C Tarumi; Y Watanabe
Journal:  Biochim Biophys Acta       Date:  1986-06-11

9.  Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on mitochondrial respiration in ischemic rat hearts.

Authors:  K Satoh; K Ichihara
Journal:  Eur J Pharmacol       Date:  1995-03-16       Impact factor: 4.432

10.  Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS)

Authors: 
Journal:  Lancet       Date:  1994-09-03       Impact factor: 79.321

View more
  9 in total

Review 1.  Oxidative stress as a possible mechanism of statin-induced myopathy.

Authors:  Yasin Ahmadi; Amir Ghorbanihaghjo; Mohsen Naghi-Zadeh; Neda Lotfi Yagin
Journal:  Inflammopharmacology       Date:  2018-03-24       Impact factor: 4.473

2.  Coenzyme Q10 and cognition in atorvastatin treated dogs.

Authors:  Sarah B Martin; Giovanna Cenini; Eugenio Barone; Amy L S Dowling; Cesare Mancuso; D Allan Butterfield; M Paul Murphy; Elizabeth Head
Journal:  Neurosci Lett       Date:  2011-07-08       Impact factor: 3.046

3.  Mitophagy is required for acute cardioprotection by simvastatin.

Authors:  Allen M Andres; Genaro Hernandez; Pamela Lee; Chengqun Huang; Eric P Ratliff; Jon Sin; Christine A Thornton; Marichris V Damasco; Roberta A Gottlieb
Journal:  Antioxid Redox Signal       Date:  2013-09-20       Impact factor: 8.401

Review 4.  Pravastatin. A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease.

Authors:  M Haria; D McTavish
Journal:  Drugs       Date:  1997-02       Impact factor: 9.546

Review 5.  Statins more than cholesterol lowering agents in Alzheimer disease: their pleiotropic functions as potential therapeutic targets.

Authors:  Eugenio Barone; Fabio Di Domenico; D Allan Butterfield
Journal:  Biochem Pharmacol       Date:  2013-11-11       Impact factor: 5.858

6.  Statin-Associated Cardiomyopathy Responds to Statin Withdrawal and Administration of Coenzyme Q10.

Authors:  Peter H Langsjoen; Jens O Langsjoen; Alena M Langsjoen; Franklin Rosenfeldt
Journal:  Perm J       Date:  2019-08-26

7.  Effects of simvastatin on cardiohemodynamic responses to ischemia-reperfusion in isolated rat hearts.

Authors:  Xia Zheng; Shen-Jiang Hu
Journal:  Heart Vessels       Date:  2006-03       Impact factor: 2.037

Review 8.  Statin adverse effects : a review of the literature and evidence for a mitochondrial mechanism.

Authors:  Beatrice A Golomb; Marcella A Evans
Journal:  Am J Cardiovasc Drugs       Date:  2008       Impact factor: 3.571

9.  Cardiovascular effects of resveratrol and atorvastatin treatments in an H2O2-induced stress model.

Authors:  Burak Cem Soner; Ayşe Saide Sahin
Journal:  Exp Ther Med       Date:  2014-09-11       Impact factor: 2.447

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.